IPO - Kairos Pharma, LTD.

Form Type: CORRESP

Filing Date: 2025-04-22

Corporate Action: Ipo

Type: New

Accession Number: 000164117225005650

Filing Summary: Kairos Pharma, Ltd. has requested the acceleration of the effective date of its registration statement on Form S-1 (File No. 333-286662), aiming for the effective date to be on April 24, 2025, at 5:00 PM Eastern Time. This request is made pursuant to Rule 461 under the Securities Act of 1933. The Registrant has authorized Megan J. Penick, Esq. from Dorsey & Whitney LLP to make the request on its behalf. The filing is significant as it relates to the company’s initial public offering plans.

Form Type: S-1

Filing Date: 2025-04-22

Corporate Action: Ipo

Type: New

Accession Number: 000164117225005602

Filing Summary: Kairos Pharma, Ltd. is filing a registration statement on Form S-1 regarding the proposed offering and sale of approximately 16,295,641 shares of common stock. The proposed sale includes up to $15 million of shares to be issued under an equity line of credit agreement with Helena Global Investment Opportunities I Ltd. This Form S-1 marks the company's intent to initiate public securities offerings following its status as a clinical-stage biopharmaceutical company focused on developing therapeutic drugs for various cancers. The document outlines their strategic approach to cancer treatment, which includes addressing drug resistance and immune suppression. The filing includes information about their developmental pipeline, consisting of seven drug candidates with promising therapeutic potential, particularly in prostate and lung cancers. Specific mention is made of ongoing and planned clinical trials, through which they aim to bring innovative solutions to the market. The document indicates that the company will not receive any proceeds from the sale of shares by the Selling Stockholder, as those securities are to be registered for resale purposes. Additionally, it highlights the company's status as an emerging growth company, allowing them to meet certain reduced reporting requirements, and presents an overview of their business strategy to transform the future of cancer treatment through innovative therapies and technologies.

Form Type: S-1

Filing Date: 2025-01-29

Corporate Action: Ipo

Type: New

Accession Number: 000149315225004041

Filing Summary: Kairos Pharma, Ltd. is filing a Form S-1 registration statement with the SEC to offer up to 6,425,000 shares of common stock, consisting of shares underlying pre-funded warrants, common warrants, and placement agent warrants. The offering includes 2,500,000 shares underlying pre-funded warrants, 3,750,000 shares underlying common warrants issued in a PIPE Offering, and 175,000 shares underlying placement agent warrants. The company will not receive proceeds from the resale of these shares but may receive up to approximately $5.5 million from the exercise of the warrants. Proceeds from any warrant exercise are intended to fund clinical trials, potential acquisitions, and general corporate purposes. The company is classified as an emerging growth company and will utilize reduced reporting requirements. Their common stock is listed on NYSE American under the symbol 'KAPA,' with a last reported sale price of $1.53 per share on January 27, 2025. The registration is intended for delayed or continuous offering and the final effective date will be determined by the SEC. As such, investments in their securities carry a high degree of risk, which is discussed in the risk factors section of the prospectus.

Form Type: DRS

Filing Date: 2025-01-03

Corporate Action: Ipo

Type: New

Accession Number: 000149315225000210

Filing Summary: Kairos Pharma, Ltd. has submitted a confidential draft registration statement under Form S-1 for an initial public offering (IPO) of common stock to raise funds from the public. The registration statement relates to the offer and sale of up to $10 million worth of shares by Helena Global Investment Opportunities I Ltd. under an equity line of credit established in November 2024. The statement indicates that the proceeds will not be received directly by Kairos but will be from the sale of shares by the selling stockholder, Helena. Kairos is currently delineating its innovative portfolio of therapeutic agents primarily targeted at overcoming drug resistance and immune suppression in cancer treatment, featuring several drug candidates developed through strategic collaborations. The SEC registration is confidential and has not been filed publicly yet, adhering to the emergent growth company guidelines. The anticipated commencement of the public offering is set to be as soon as practicable following the effectiveness of the registration statement.